LB

Louis Bock

Venture Partner at Santé Ventures

Austin, Texas

Overview

Work Experience

  • Venture Partner

    2014 - Current

    Early-Stage healthcare and life science investment firm

  • Board Director

    2006

    Zogenix (NASDAQ: ZGNX) is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning

  • Board Director

    2013

    Pwervision is developing the FluidVision® accommodating intraocular lens (IOL). This technology will restore the vision of youth to middle aged or elderly individuals affected by presbyopia and/or cataracts. The Company's mission is to provide a family of fluid based lens implants that solve clinical and lifestyle needs caused by these conditions thereby creating the most significant innovation in vision correction surgery since the introduction of the IOL.

  • Board Director

    2005

    SkySong Innovations is the exclusive intellectual property management and technology transfer organization for Arizona State University (ASU). We work with faculty, investors and our industry partners to translate ASU innovation into broad societal impact.

  • Board Director

    2005 - 2018

    Orexigen Therapeutics, Inc. was a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014. In Europe the drug has been approved under the brand name Mysimba® (naltrexone HCl/ bupropion HCl prolonged release).

  • Board Director

    2013 - 2017

    Molecular Templates is a biotechnology company focused on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers and other serious disease

  • Board Director

    2013 - 2017

    Cardiokinetix, based in Menlo Park, CA, has developed a novel transcatheter implant called the Parachute® Ventricular Partitioning Device (Parachute). The Parachute intends to treat heart failure resulting from a heart attack in patients worldwide by improving overall cardiac function.

  • Board Director

    2013 - 2016

    Heat Biologics (NASDAQ: HTBX) is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic cell based immunotherapy for use in the treatment of a wide range of cancers and infectious diseases.

  • Board Director

    2010 - 2014

    Hospice is a program of care and support for a person diagnosed with a terminal illness and comfort care is desired. Helping people find meaning and peace is at the core of our mission. At New Century Hospice, our program supports early involvement where a dramatic difference in the quality of life can be experienced. By enabling families and loved ones to participate in the care experience, we are able to make the remaining time more meaningful, dignified and comfortable.

  • Partner & Co-Founder

    1997 - 2014

    Scale Venture Partners is a venture capital firm that invests primarily in early-in-revenue technology companies with a focus on Internet, cloud computing, software as a service, and mobile products. The firm is based in Foster City, California https://www.scalevp.com

Relevant Websites